sugemalimab
cstone pharmaceuticals
['lymsm', 'sugemalimab', 'lymphoma']
treatment with #sugemalimab is well-tolerated and shows promise in patients with relapsed or refractory extranodal natural killer/t cell lymphoma. #lymsm #asco22 
Oncology news and insights from leading researchers and cancer centers.